Market revenue in 2023 | USD 2,268.5 million |
Market revenue in 2030 | USD 5,945.0 million |
Growth rate | 14.8% (CAGR from 2023 to 2030) |
Largest segment | Phase ii |
Fastest growing segment | Phase III |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.
Phase ii was the largest segment with a revenue share of 50.51% in 2023. Horizon Databook has segmented the Europe cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Countries such as Germany and the UK have a large patient pool and advanced medical expertise. The doctors advocate for these trials, thus increasing patient recruitment and benefiting research and patients. The legal aspects are in a developing stage in Germany but are fully evolved in the UK and France. The regulations are formulated to ensure the safety, rights, and proper reimbursement of volunteers.
With clearer protocols and increased funding, Europe is expected to be a promising region for cell and gene therapy clinical trials. Factors such as greater access to treatment-naïve patient pool, higher concentration of patients near sites, cheap labor costs, and close relationship between doctors and patients are driving the clinical research market in Europe.
For example, a new Clinical Trials Regulation would be introduced across the EU by 2022 to streamline and standardize the application and monitoring of clinical trials across EU Member States. In the near future, the legislation will require all clinical trial applications in the EU involving medicinal goods in people to be submitted through a new Clinical Studies Information System (CTIS), as well as many changes concentrating on ongoing clinical trials.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe cell and gene therapy clinical trials market , including forecasts for subscribers. This continent databook contains high-level insights into Europe cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account